Results
In the study, thirty-three were
included. Patients’ basic features are shown in Table 1 .
According to preoperative imaging material, the patients with a single
tumor had 23 cases(69.7%),and a total of 10 patients(30.3%) has two
and more tumors.10cm was defined as dividing point of tumor diameter,21
cases(63.6%) were smaller than 10cm, and 12 cases(36.4%) were larger
than 10cm. The median of operation time was 200 min(110-360min),18
cases(54.5%) of them were over 200min. Portal vein occlusion occurred
in 12 patients(36.4%), 8 cases(24.2%) of them occluded once,2
cases(6.1%) occluded twice and 2 cases (6.1%) occluded thrice. The
boundary was15 min and 6 cases(18.2) were greater than 15 min. There
were 15 cases(45.5%) of intrahepatic recurrence only. Patients with
intrahepatic recurrence received vertebroplasty combined chemotherapy
(VPCC), targeted therapy ,TACE and radio frequency catheter
ablation(RFCA) in 1(3%),1(3%),10(30.3%) and 7(12.1%) cases
respectively. The median levels of AFP and CA-199 before PM were
77.12ug/L(1.06-121000 ug/L) and 29.05 ug/L(1.21-84.79 ug/L) and greater
than normal revel were 22(66.7%) and 18(54.5%) cases respectively. All
patients with PM received chemotherapy until death or the end of the
study. Each patient was presented with detailed information inTable 2 .
The 2- and 3- year cumulative probability of OS from LLR or OLR were
63% and 41%. The median OS was 30.8 months(95%CI 22.0-39.5)
(Figure1a ). The median recurrence time was 6 months(1.7-4.8
months) after liver resection. The patients with intrahepatic recurrence
who underwent OLR and LLR had higher OS than patients without
intrahepatic
recurrence(P=0.04)(Figure1
b ). The OS of patients with intrahepatic recurrence who received VPCC,
targeted therapy, TACE and RFCA was higher (P=0.03)( Figure1
c ).The median of confirmed PM time from HCC was 12.5 months(1.5-61.1
months) and 17(51.5%) patients died. Meanwhile, the OS of patients with
late PM was significantly higher than that of patients with early PM
time(P=0.02)( Figure1 d ).
Table 1. Basic features of the 33 patients included in the study.